U.S. Agencies Seek Balance In Biotechnology Rules

WASHINGTON-Government agencies, in their zeal to demonstrate support for biotechnology research, may have unintentionally complicated efforts to regulate the burgeoning field, according to federal officials. "We have opened up a complex regulatory world that need not have been," asserted David Kingsbury of the National Science Foundation. There is a growing "tendency to 'do' all of biology," he added, as conscientious regulators "examine things that have been going on for long periods of time. W

Written byJeffrey Fox
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

WASHINGTON-Government agencies, in their zeal to demonstrate support for biotechnology research, may have unintentionally complicated efforts to regulate the burgeoning field, according to federal officials.

"We have opened up a complex regulatory world that need not have been," asserted David Kingsbury of the National Science Foundation. There is a growing "tendency to 'do' all of biology," he added, as conscientious regulators "examine things that have been going on for long periods of time. We may have done ourselves some mischief."

Kingsbury, associate director for biological, behavioral and social sciences at the science foundation, also chairs the committee that is overseeing the federal effort to co ordinate biotechnology regulations and guidelines. He spoke during a one-day workshop last month on public funding of biotechnology research and training convened by the Office of Technology Assessment.

The various agencies involved in supporting biotechnology found themselves in a dilemma as interest in the subject ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies